Navigation Links
Titanium Group Signs Letter of Intent to Acquire Multimilion Dollar Medical Software Company and Its Existing Sales Network
Date:11/21/2007

Company Anticipates Acquisition Could More Than Double its Current Revenue Stream and Fuel Market Entry Into the Medical and Healthcare Industry

SAN JOSE, Calif., Nov. 2 /PRNewswire-FirstCall/ -- Titanium Group Limited (OTC Bulletin Board: TTNUF), a leading biometric and security solutions provider, announced today the company has signed a letter of intent to acquire China Medical Systems (OTC: CHSY), a company listed in the US that engages in researching, developing and marketing of specialized software systems in the field of three-dimensional medical imaging. Their major products include Virtual Endoscopy and 3D Virtual Radiotherapy Planning System. China Medical Systems is profitable and had revenues of US$2.2 million in 2006. The acquisition could not only further boost Titanium's research and development capability in the areas of image processing and pattern recognition, but also provide a sales channel into China's healthcare and medical industry.

"The acquisition of China Medical Systems represents great synergies. First of all, like Titanium their core value lies in the research and development of software technology. Their expertise in image processing will add value to Titanium's video surveillance technology. Secondly, as medical care reform in the PRC has started we have identified the medical and health care industry as an important sector for Titanium's products. The acquisition would allow us to pursue new customers and market segments through China Medical Systems' existing sales network," said Johnny Ng, Chairman of Titanium Group Limited. "In addition, China Medical Systems could also double our current revenue stream which would add to our shareholder value."

The completion of the acquisition is subject to completion of further due diligence and financing and execution of a definitive agreement.

About Titanium Group:

Titanium Group Limited (http://www.titanium-tech.com), through its wholly owned subsidiary Titanium Technology, is a leading biometric and security solutions provider featuring its proprietary and patented automated Face Recognition Systems (AFRS). Titanium's AFRS products capture human face images electronically, input the facial images into searchable files (face print) and, in just seconds, accurately compare the facial images to a database containing millions of faces. These cutting-edge products reduce administration cost, enhance security, and significantly increase overall productivity. Titanium's products are distributed worldwide, either directly or through resellers or OEM partners, to governments, law enforcement agencies, gaming companies, and other organizations. The Company's clients include: ESPN, IBM and the People's Bank of China.

About China Medical Systems:

China Medical Systems (http://www.sxgk.cn/en) is listed on the Pink Sheets with trading Symbol CHSY. The company is engaged in manufacturing, developing and selling three-dimensional medical imaging software such as Virtual Endoscopy (Virtual Colonoscopy) which allows doctors to transform a medical image from the patient's CT image and examine the full large intestinal wall to diagnose the state of an illness or to discover the knubs in the intestines. Other products also include three-dimensional virtual radioactive therapy system and medical image pool products.

Safe Harbor Provisions

Certain oral statements made by management from time to time and certain statements contained in press releases and periodic reports issued by Titanium Group Limited (the "Company"), as well as those contained herein, that are not historical facts are "forward-looking statements" and, because such statements involve risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements are statements regarding the intent, belief or current expectations, estimates or projections of the Company, its Directors or its Officers about the Company and the industry in which it operates, and are based on assumptions made by management. Forward-looking statements include without limitation statements regarding: (a) the Company's strategies regarding growth and business expansion, including future acquisitions; (b) the Company's financing plans; (c) trends affecting the Company's financial condition or results of operations; (d) the Company's ability to continue to control costs and to meet its liquidity and other financing needs; (e) the declaration and payment of dividends; and (f) the Company's ability to respond to changes in customer demand and regulations. Although the Company believes that its expectations are based on reasonable assumptions, it can give no assurance that the anticipated results will occur. When issued in this report, the words "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," and similar expressions are generally intended to identify forward-looking statements.

Important factors that could cause the actual results to differ materially from those in the forward-looking statements include, among other items, (i) changes in the regulatory and general economic environment; (ii) conditions in the capital markets, including the interest rate environment and the availability of capital; (iii) changes in the competitive marketplace that could affect the Company's revenue and/or cost and expenses, such as increased competition, lack of qualified marketing, management or other personnel, and increased labor and inventory costs; (iv) changes in technology or customer requirements, which could render the Company's technologies noncompetitive or obsolete; and (v) new product introductions, product sales mix and the geographic mix of sales.

The Company disclaims any intention or obligation to update or revise forward-looking statements, whether as a result of new information, future events or otherwise. The statements which are not historical facts contained in this advertisement are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, governmental approval processes, the impact of competitive products or pricing, technological changes, and the effect of economic conditions.


'/>"/>
SOURCE Titanium Group Limited
Copyright©2007 PR Newswire.
All rights reserved

Related biology news :

1. Titanium Group Announces Contract With Haitong Securities
2. Titanium Group Signs Letter of Intent to Acquire Multimilion Dollar Medical Software Company and Its Existing Sales Network
3. Titanium Group to Showcase Products and Technologies in Prestigious Government Seminar
4. Study identifies warning signs of pregnancy danger
5. Study finds environmental tests help predict hospital-acquired Legionnaires disease risk
6. bioMETRX, Inc. Acquires Patent for Biometric Padlock
7. Image Solutions, Inc. Acquires Zurich Biostatistics, Inc.
8. bioMETRX, Inc. Acquires Patent for Biometric Padlock
9. Argonne National Lab acquires first SiCortex SC5832
10. American College of Medical Genetics responds to new FDA labeling decision for warfarin
11. M2SYS Partners With Gnosis Medical Services to Provide Accurate Patient Identification in Developing Countries Through Innovative Biometrics Solution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/7/2017)... 7, 2017   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that the ... innovative, highly flexible and award winning eClinical solution, is ... iMedNet is a proven Software-as-a-Service (SaaS) clinical research ... (EDC), but also delivers an entire suite of eClinical ...
(Date:2/6/2017)... Feb. 6, 2017 According to Acuity ... driving border authorities to continue to embrace biometric ... are 2143 Automated Border Control (ABC) eGates and ... at more than 163 ports of entry across ... 2016 achieving a combined CAGR of 37%. APC ...
(Date:2/2/2017)... , Feb. 2, 2017   TapImmune, ... clinical-stage immuno-oncology company specializing in the development of ... the treatment of cancer and metastatic disease, announced ... and GMP manufacturing of a second clinical lot ... targeting folate receptor alpha. The manufactured vaccine product ...
Breaking Biology News(10 mins):
(Date:2/18/2017)... , Feb 17, 2017 Research and ... Strategic Business Report" report to their offering. ... The report provides separate comprehensive ... Europe , and Rest of World. Annual estimates and forecasts ... historic analysis is provided for these markets. Market data and analytics ...
(Date:2/17/2017)...  If only one in every hundred cells ... to chemotherapy, thousands of cancer cells would remain ... finding these mutations in ever-smaller subpopulations of tumor ... in blood — to guide treatment decisions and ... however, detecting these genetic anomalies may be more ...
(Date:2/16/2017)... ... February 16, 2017 , ... EIT Digital has ... at the agricultural industry. Pilot studies are about to get under way for the ... Data and 5G innovations. The concept is expected to be transferred eventually to other ...
(Date:2/16/2017)... GREENWICH, Conn. , Feb. 16, ... focused on venture growth investments in biotechnology and ... Josh Richardson , M.D. to Managing Director. ... companies.  He is a board observer at InfaCare ... Longitude,s investments in Aimmune Therapeutics, Akebia Therapeutics, Cadence ...
Breaking Biology Technology: